7 results on '"Loeser, K."'
Search Results
2. Distortion Control by Innovative Heat Treating Technologies in the Automotive Industry*
- Author
-
Loeser, K., primary, Heuer, V., additional, and Faron, D. R., additional
- Published
- 2006
- Full Text
- View/download PDF
3. Exploration of Long-Chain Vitamin e Metabolites for the Discovery of a Highly Potent, Orally Effective, and Metabolically Stable 5-LOX Inhibitor that Limits Inflammation
- Author
-
Andreas Koeberle, Denis Séraphin, Stefan Lorkowski, Tiago Rodrigues, Oliver Werz, Daniela Schuster, Dimitri Bréard, Hermann Stuppner, Ida Cerqua, Antonietta Rossi, Simona Pace, Marta C. Marques, Alexander S. Mosig, Paul M. Jordan, Stephan Permann, Jana Gerstmeier, Martin Raasch, Gonçalo J. L. Bernardes, André Gollowitzer, Ulrike Garscha, Chau-Phi Dinh, Alexia Ville, Jean-Jacques Helesbeux, Fiorentina Roviezzo, Guillaume Viault, Elena Brunner, Pascal Richomme, Veronika Temml, Rossella Bilancia, Khaled Alsabil, Konstantin Loeser, Konstantin Neukirch, Neukirch, K., Alsabil, K., Dinh, C. -P., Bilancia, R., Raasch, M., Ville, A., Cerqua, I., Viault, G., Breard, D., Pace, S., Temml, V., Brunner, E., Jordan, P. M., Marques, M. C., Loeser, K., Gollowitzer, A., Permann, S., Gerstmeier, J., Lorkowski, S., Stuppner, H., Garscha, U., Rodrigues, T., Bernardes, G. J. L., Schuster, D., Seraphin, D., Richomme, P., Rossi, A., Mosig, A. S., Roviezzo, F., Werz, O., Helesbeux, J. -J., Koeberle, A., Neukirch, Konstantin [0000-0003-0630-1624], Dinh, Chau-Phi [0000-0002-3683-3472], Gollowitzer, André [0000-0003-1524-8298], Stuppner, Hermann [0000-0001-8862-0201], Rodrigues, Tiago [0000-0002-1581-5654], Bernardes, Gonçalo J L [0000-0001-6594-8917], Schuster, Daniela [0000-0002-9933-8938], Séraphin, Denis [0000-0002-0509-5788], Mosig, Alexander S [0000-0002-5687-2444], Werz, Oliver [0000-0002-5064-4379], Koeberle, Andreas [0000-0001-6269-5088], Apollo - University of Cambridge Repository, and Bernardes, Gonçalo JL [0000-0001-6594-8917]
- Subjects
medicine.medical_treatment ,Administration, Oral ,Inflammation ,Endogeny ,Lipoxygenase Inhibitor ,Pharmacology ,Article ,chemistry.chemical_compound ,Structure-Activity Relationship ,Immune system ,Drug Discovery ,medicine ,Humans ,Vitamin E ,Lipoxygenase Inhibitors ,Prostaglandin E2 ,Leukotriene ,Arachidonate 5-Lipoxygenase ,Dose-Response Relationship, Drug ,Molecular Structure ,Chemistry ,Lipid signaling ,Recombinant Protein ,Recombinant Proteins ,Molecular Docking Simulation ,Molecular Medicine ,medicine.symptom ,Resolvin ,medicine.drug ,Human - Abstract
Endogenous long-chain metabolites of vitamin E (LCMs) mediate immune functions by targeting 5-lipoxygenase (5-LOX) and increasing the systemic concentrations of resolvin E3, a specialized proresolving lipid mediator. SAR studies on semisynthesized analogues highlight α-amplexichromanol (27a), which allosterically inhibits 5-LOX, being considerably more potent than endogenous LCMs in human primary immune cells and blood. Other enzymes within lipid mediator biosynthesis were not substantially inhibited, except for microsomal prostaglandin E2 synthase-1. Compound 27a is metabolized by sulfation and β-oxidation in human liver-on-chips and exhibits superior metabolic stability in mice over LCMs. Pharmacokinetic studies show distribution of 27a from plasma to the inflamed peritoneal cavity and lung. In parallel, 5-LOX-derived leukotriene levels decrease, and the inflammatory reaction is suppressed in reconstructed human epidermis, murine peritonitis, and experimental asthma in mice. Our study highlights 27a as an orally active, LCM-inspired drug candidate that limits inflammation with superior potency and metabolic stability to the endogenous lead.
- Published
- 2021
4. Attenuated growth factor signaling during cell death initiation sensitizes membranes towards peroxidation.
- Author
-
Gollowitzer A, Pein H, Rao Z, Waltl L, Bereuter L, Loeser K, Meyer T, Jafari V, Witt F, Winkler R, Su F, Große S, Thürmer M, Grander J, Hotze M, Harder S, Espada L, Magnutzki A, Gstir R, Weinigel C, Rummler S, Bonn G, Pachmayr J, Ermolaeva M, Harayama T, Schlüter H, Kosan C, Heller R, Thedieck K, Schmitt M, Shimizu T, Popp J, Shindou H, Kwiatkowski M, and Koeberle A
- Subjects
- Humans, Cell Membrane metabolism, Sterol Regulatory Element Binding Protein 1 metabolism, Sterol Regulatory Element Binding Protein 1 genetics, Proto-Oncogene Proteins c-akt metabolism, Phospholipids metabolism, Fatty Acids, Unsaturated metabolism, Cell Death, Coenzyme A Ligases metabolism, Coenzyme A Ligases genetics, Animals, Phosphatidylinositol 3-Kinases metabolism, Oxidation-Reduction, Oxidative Stress, Ferroptosis, Signal Transduction, Lipid Peroxidation, Apoptosis
- Abstract
Cell death programs such as apoptosis and ferroptosis are associated with aberrant redox homeostasis linked to lipid metabolism and membrane function. Evidence for cross-talk between these programs is emerging. Here, we show that cytotoxic stress channels polyunsaturated fatty acids via lysophospholipid acyltransferase 12 into phospholipids that become susceptible to peroxidation under additional redox stress. This reprogramming is associated with altered acyl-CoA synthetase isoenzyme expression and caused by a decrease in growth factor receptor tyrosine kinase (RTK)-phosphatidylinositol-3-kinase signaling, resulting in suppressed fatty acid biosynthesis, for specific stressors via impaired Akt-SREBP1 activation. The reduced availability of de novo synthesized fatty acids favors the channeling of polyunsaturated fatty acids into phospholipids. Growth factor withdrawal by serum starvation mimics this phenotype, whereas RTK ligands counteract it. We conclude that attenuated RTK signaling during cell death initiation increases cells' susceptibility to oxidative membrane damage at the interface of apoptosis and alternative cell death programs., Competing Interests: Competing interests: The authors declare no competing interests., (© 2025. The Author(s).)
- Published
- 2025
- Full Text
- View/download PDF
5. Exploration of Long-Chain Vitamin E Metabolites for the Discovery of a Highly Potent, Orally Effective, and Metabolically Stable 5-LOX Inhibitor that Limits Inflammation.
- Author
-
Neukirch K, Alsabil K, Dinh CP, Bilancia R, Raasch M, Ville A, Cerqua I, Viault G, Bréard D, Pace S, Temml V, Brunner E, Jordan PM, Marques MC, Loeser K, Gollowitzer A, Permann S, Gerstmeier J, Lorkowski S, Stuppner H, Garscha U, Rodrigues T, Bernardes GJL, Schuster D, Séraphin D, Richomme P, Rossi A, Mosig AS, Roviezzo F, Werz O, Helesbeux JJ, and Koeberle A
- Subjects
- Administration, Oral, Arachidonate 5-Lipoxygenase genetics, Dose-Response Relationship, Drug, Humans, Inflammation metabolism, Lipoxygenase Inhibitors administration & dosage, Lipoxygenase Inhibitors metabolism, Molecular Docking Simulation, Molecular Structure, Recombinant Proteins genetics, Recombinant Proteins metabolism, Structure-Activity Relationship, Vitamin E administration & dosage, Vitamin E metabolism, Arachidonate 5-Lipoxygenase metabolism, Drug Discovery, Inflammation drug therapy, Lipoxygenase Inhibitors pharmacology, Vitamin E pharmacology
- Abstract
Endogenous long-chain metabolites of vitamin E (LCMs) mediate immune functions by targeting 5-lipoxygenase (5-LOX) and increasing the systemic concentrations of resolvin E3, a specialized proresolving lipid mediator. SAR studies on semisynthesized analogues highlight α-amplexichromanol ( 27a ), which allosterically inhibits 5-LOX, being considerably more potent than endogenous LCMs in human primary immune cells and blood. Other enzymes within lipid mediator biosynthesis were not substantially inhibited, except for microsomal prostaglandin E
2 synthase-1. Compound 27a is metabolized by sulfation and β-oxidation in human liver-on-chips and exhibits superior metabolic stability in mice over LCMs. Pharmacokinetic studies show distribution of 27a from plasma to the inflamed peritoneal cavity and lung. In parallel, 5-LOX-derived leukotriene levels decrease, and the inflammatory reaction is suppressed in reconstructed human epidermis, murine peritonitis, and experimental asthma in mice. Our study highlights 27a as an orally active, LCM-inspired drug candidate that limits inflammation with superior potency and metabolic stability to the endogenous lead.- Published
- 2021
- Full Text
- View/download PDF
6. Protective Effect of Casperome ® , an Orally Bioavailable Frankincense Extract, on Lipopolysaccharide- Induced Systemic Inflammation in Mice.
- Author
-
Loeser K, Seemann S, König S, Lenhardt I, Abdel-Tawab M, Koeberle A, Werz O, and Lupp A
- Abstract
Introduction: Despite recent advances in critical care, sepsis remains a crucial cause of morbidity and mortality in intensive care units. Therefore, the identification of new therapeutic strategies is of great importance. Since ancient times, frankincense is used in traditional medicine for the treatment of chronic inflammatory disorders such as rheumatoid arthritis. Thus, the present study intends to evaluate if Casperome
® (Casp), an orally bioavailable soy lecithin-based formulation of standardized frankincense extract, is able to ameliorate systemic effects and organ damages induced by severe systemic inflammation using a murine model of sepsis, i.e., intraperitoneal administration of lipopolysaccharides (LPS). Methods: Male 60-day-old mice were assigned to six treatment groups: (1) control, (2) LPS, (3) soy lecithin (blank lecithin without frankincense extract), (4) Casp, (5) soy lecithin plus LPS, or (6) Casp plus LPS. Soy lecithin and Casp were given 3 h prior to LPS treatment; 24 h after LPS administration, animals were sacrificed and health status and serum cytokine levels were evaluated. Additionally, parameters representing liver damage or liver function and indicating oxidative stress in different organs were determined. Furthermore, markers for apoptosis and immune cell redistribution were assessed by immunohistochemistry in liver and spleen. Results: LPS treatment caused a decrease in body temperature, blood glucose levels, liver glycogen content, and biotransformation capacity along with an increase in serum cytokine levels and oxidative stress in various organs. Additionally, apoptotic processes were increased in spleen besides a pronounced immune cell infiltration in both liver and spleen. Pretreatment with Casp significantly improved health status, blood glucose values, and body temperature of the animals, while serum levels of pro-inflammatory cytokines and oxidative stress in all organs tested were significantly diminished. Finally, apoptotic processes in spleen, liver glycogen loss, and immune cell infiltration in liver and spleen were distinctly reduced. Casp also appears to induce various cytochromeP450 isoforms, thus causing re-establishment of liver biotransformation capacity in LPS-treated mice. Conclusion: Casp displayed anti-inflammatory, anti-oxidative, and hepatoprotective effects. Thus, orally bioavailable frankincense extracts may serve as a new supportive treatment option in acute systemic inflammation and accompanied liver dysfunction.- Published
- 2018
- Full Text
- View/download PDF
7. Vitamin A regulates Akt signaling through the phospholipid fatty acid composition.
- Author
-
Pein H, Koeberle SC, Voelkel M, Schneider F, Rossi A, Thürmer M, Loeser K, Sautebin L, Morrison H, Werz O, and Koeberle A
- Subjects
- Animals, Cell Proliferation drug effects, Mice, Phosphorylation, Retinoid X Receptors metabolism, Tretinoin metabolism, Vitamin A pharmacology, Fatty Acids metabolism, Phospholipids metabolism, Proto-Oncogene Proteins c-akt metabolism, Signal Transduction drug effects, Tretinoin pharmacology, Vitamin A metabolism
- Abstract
Protein kinases, including the serine/threonine kinase Akt, mediate manifold bioactivities of vitamin A, although the mechanisms behind the sustained kinase activation are diffuse. To investigate the role of cellular lipids as targetable factors in Akt signaling, we combined mass spectrometry-based lipidomics with immunologic detection of Akt (Ser473) phosphorylation. A screening campaign revealed retinol (vitamin A alcohol) and all- trans retinoic acid (vitamin A acid) (RA) as hits that time-dependently (≥24 h) deplete phosphatidylcholine-bound polyunsaturated fatty acids (PUFA-PCs) from NIH-3T3 mouse fibroblasts while inducing Akt activation (EC
50 ≈ 0.1-1 µM). Other mitogenic and stress-regulated kinases were hardly affected. Organized in a coregulated phospholipid subcluster, PUFA-PCs compensated for the RA-induced loss of cellular PUFA-PCs and diminished Akt activation when supplemented. The counter-regulation of phospholipids and Akt by RA was mimicked by knockdown of lysophosphatidylcholine acyltransferase-3 or the selective retinoid X receptor (RXR) agonist bexarotene and prevented by the selective RXR antagonist Hx531. Treatment of mice with retinol decreased the tissue ratio of PUFA-PC and enhanced basal Akt activation preferentially in brain, which was attributed to astrocytes in dissociated cortical cultures. Together, our findings show that RA regulates the long-term activation of Akt by changes in the phospholipid composition.-Pein, H., Koeberle, S. C., Voelkel, M., Schneider, F., Rossi, A., Thürmer, M., Loeser, K., Sautebin, L., Morrison, H., Werz, O., Koeberle, A. Vitamin A regulates Akt signaling through the phospholipid fatty acid composition., (© FASEB.)- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.